A Phase 1 interventional study of Benralizumab and Benralizumab in Asthma and Chronic Obstructive Pulmonary Disease, sponsored by AstraZeneca. Completed at 2 sites in Germany. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-07-05.
Sponsored by AstraZeneca · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 39 studies testing benralizumab in Asthma — 3 open to participants now, 4 under way, 2 of them phase 3. benralizumab · Asthma.
Among the 39 studies testing benralizumab in Asthma, this one is the 14th largest by enrollment, is one of 4 that started in 2017, is one of 3 in phase 1, and was the 19th registered.
4,848 studies on the registry are indexed under Asthma; 605 are open to participants now.
Browse Asthma studies →3 of the 39 studies testing benralizumab in Asthma are open now, in 12 countries. Recruiting first, the newest first:
AstraZeneca · Sites in United States, Argentina, Austria and 11 more countries
Ages 6+
University of California, San Diego · Sites in United States
Ages 18–75
Endeavor Health · Sites in United States
Ages 18+
By country, each count listing its studies:
benralizumab: first FDA approval 2017 (FASENRA), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →
Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.
This study: 18 Years to 55 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
39 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 4 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 180 is above the median of 79 across 3,344 interventional studies indexed under Asthma.
Median enrollment 128 across the 39 interventional studies. Of the 31 that completed or were terminated, 24 (77%) have results posted.
This tab as a report to print or save as PDF → With an account.
30 of 39 have an industry lead sponsor. The 10 most frequent:
AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
359 studies in Asthma by AstraZeneca: 19 open now, 28 under way, 8 of them phase 3. Of 330 finished, 129 (39%) have results posted.
Among the 359 studies in Asthma by AstraZeneca, this one is the 122nd largest by enrollment of the 248 interventional ones that give a count, is one of 13 that started in 2017, is one of 46 in phase 1, and was the 220th registered.
AstraZeneca’s Asthma studies by the year they started, since 1996.
3 of the studies testing benralizumab in Asthma that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05692180Phase 3AstraZenecaA Multicentre, Randomised, Double-blind, Parallel Group, Placebo-controlled, Time-to-first Asthma Exacerbation Phase III Efficacy and Safety Study of Benralizumab in Paediatric Patients With Severe Eosinophilic Asthma | 2026-12-23 |
| NCT06385236University of California, San DiegoLeveraging Pharmacogenomics in Asthma for Predication, Mechanism and Endotyping | 2027-06-30 |
| NCT07654842Endeavor HealthFasenra: An Asthma Study | 2027-09-01 |
Add all 3 to your calendar (.ics) → With an account.
Among the 39 studies testing benralizumab in Asthma, from their registry updates:
Among AstraZeneca’s 359 in Asthma:
This tab as a report to print or save as PDF → With an account.
An open-label, single dose Pharmacokinetic (PK) comparability study to demonstrate comparable drug exposure following Subcutaneous benralizumab administration by using accessorized pre-filled syringe (APFS) or autoinjector (AI) devices.
A study of descriptive comparison of benralizumab PK by weight and injection site.
This study will be a multicenter, randomized, open-label, parallel group Phase 1 study designed to compare benralizumab PK exposure in healthy subjects following single subcutaneous (SC) administration of fixed 30 mg dose of benralizumab by using APFS and single-use AI. Eligible subjects will be healthy subjects aged 18 to 55 years, with a body weight of 55 to 100 kg and a body mass index of 18 to 29.9 kg/m2 . A total of 180 subjects will be randomized. Randomization will be stratified by weight group (55 to 69.9 kg, 70 to 84.9 kg and 85 to 100 kg), and within each of the 3 weight groups, subjects will be randomized 1:1:1:1:1:1 to 1 of the 6 combinations of treatment (APFS or AI) with injection site (upper arm, abdomen or thigh), presented in Table 1. This study will be performed at 2 study centers.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug administration by Accessorized Pre-Filled Syringe. A total of 180 subjects will be randomized and will be stratified by weight group (55 to 69.9 kg, 70 to 84.9 kg and 85 to 100 kg). Within each of the 3 weight groups, subjects will be randomized 1:1:1:1:1:1 to 1 of the 6 combinations of treatment (APFS) with injection site (upper arm, abdomen or thigh)
Biological: Benralizumab
Drug administration by Autoinjector A total of 180 subjects will be randomized and will be stratified by weight group (55 to 69.9 kg, 70 to 84.9 kg and 85 to 100 kg). Within each of the 3 weight groups, subjects will be randomized 1:1:1:1:1:1 to 1 of the 6 combinations of treatment (APFS) with injection site (upper arm, abdomen or thigh)
Biological: Benralizumab
A humanized, afucosylated, monoclonal antibody (mAb) that binds specifically to the human IL-5 receptor alpha subunit (IL-5Rα) on the target cell.
A humanized, afucosylated, monoclonal antibody (mAb) that binds specifically to the human IL-5 receptor alpha subunit (IL-5Rα) on the target cell.
Area Under the Concentration-time Curve From Zero to Infinity (AUCinf)
To compare the AUCinf following single SC administration of Benralizumab by using APFS or AI devices
Time frame: At Pre-dose (Day 1) and at Days 2, 4, 5, 6, 8, 15, 29, 43 and 57
Area Under the Concentration-time Curve From Time Zero to Time of Last Quantifiable Concentration (AUClast)
To compare the AUClast following single SC administration of Benralizumab by using APFS or AI devices
Time frame: At Pre-dose (Day 1) and at Days 2, 4, 5, 6, 8, 15, 29, 43 and 57
Maximum Observed Concentration (Cmax)
To compare the Cmax following single SC administration of Benralizumab by using APFS or AI devices
Time frame: At Pre-dose (Day 1) and at Days 2, 4, 5, 6, 8, 15, 29, 43 and 57
Time When Maximum Concentration is Observed (Tmax)
To evaluate the Tmax of Benralizumab administered to various injection sites and in subjects with different body weight ranges
Time frame: At Pre-dose (Day 1) and at Days 2, 4, 5, 6, 8, 15, 29, 43 and 57
Terminal Half-life (t½)
To evaluate the t½ of Benralizumab administered to various anatomical injection sites and in subjects with different body weight ranges.
Time frame: At Pre-dose (Day 1) and at Days 2, 4, 5, 6, 8, 15, 29, 43 and 57
Apparent Extravascular Clearance (CL/F)
To evaluate the CL/F of Benralizumab administered to various anatomical injection sites and in subjects with different body weight ranges.
Time frame: At Pre-dose (Day 1) and at Days 2, 4, 5, 6, 8, 15, 29, 43 and 57
Apparent Volume of Distribution Based on the Terminal Phase (Vz/F)
To evaluate the Vz/F of Benralizumab administered to various anatomical injection sites and in subjects with different body weight ranges.
Time frame: At Pre-dose (Day 1) and at Days 2, 4, 5, 6, 8, 15, 29, 43 and 57
Number of Participants With Adverse Events
To evaluate safety and tolerability of Benralizumab
Time frame: At predose and 2 h postdose (Day 1), Days 2, 4, 5, 6, 8, 15, 29, 43 and 57
Antidrug Antibody (ADA) Status
To evaluate the immunogenicity of Benralizumab
Time frame: At predose (Day 1), Days 29 and 57
Subjects who met all the inclusion and none of the exclusion criteria were enrolled at PAREXEL Early Phase Clinical Unit in Berlin and London.
| Milestone | Benralizumab 30mg Autoinjector (AI) | Benralizumab 30mg Accessorized Pre-filled Syringe (AFPS) |
|---|---|---|
| Started | 90 | 90 |
| Completed | 90 | 90 |
| Not completed | 0 | 0 |
To compare the AUCinf following single SC administration of Benralizumab by using APFS or AI devices
| day·ng/mL | Benralizumab 30mg AI | Benralizumab 30mg AFPS |
|---|---|---|
| Area Under the Concentration-time Curve From Zero to Infinity (AUCinf) | 72210 ± 29.7 | 76220 ± 32.1 |
To compare the AUClast following single SC administration of Benralizumab by using APFS or AI devices
| day·ng/mL | Benralizumab 30mg AI | Benralizumab 30mg AFPS |
|---|---|---|
| Area Under the Concentration-time Curve From Time Zero to Time of Last Quantifiable Concentration (AUClast) | 60560 ± 27.3 | 65230 ± 29.2 |
To compare the Cmax following single SC administration of Benralizumab by using APFS or AI devices
| ng/mL | Benralizumab 30mg AI | Benralizumab 30mg AFPS |
|---|---|---|
| Maximum Observed Concentration (Cmax) | 2096 ± 32.7 | 2269 ± 35.4 |
To evaluate the Tmax of Benralizumab administered to various injection sites and in subjects with different body weight ranges
| Days | Benralizumab 30mg AI | Benralizumab 30mg AFPS |
|---|---|---|
| Abdomen 55.0 to 69.9 kg | 4.59 (2.97 to 7.04) | 6.06 (4.00 to 14.00) |
| Abdomen 70.0 to 84.9 kg | 6.98 (3.98 to 14.00) | 5.98 (2.95 to 14.05) |
| Abdomen 85.0 to 100.0 kg | 5.06 (3.95 to 7.11) | 6.96 (3.99 to 7.10) |
| Thigh 55.0 to 69.9 kg | 4.00 (2.97 to 7.01) | 4.52 (2.94 to 7.04) |
| Thigh 70.0 to 84.9 kg | 4.05 (2.98 to 6.90) | 3.52 (2.95 to 7.12) |
| Thigh 85.0 to 100.0 kg | 4.59 (2.94 to 13.95) | 4.03 (2.98 to 6.98) |
| Upper arm 55.0 to 69.9 kg | 6.97 (3.97 to 14.02) | 4.96 (3.02 to 14.04) |
| Upper arm 70.0 to 84.9 kg | 7.00 (5.01 to 14.03) | 5.02 (2.99 to 8.01) |
| Upper arm 85.0 to 100.0 kg | 7.00 (3.09 to 14.03) | 6.97 (1.02 to 14.13) |
To evaluate the t½ of Benralizumab administered to various anatomical injection sites and in subjects with different body weight ranges.
| Days | Benralizumab 30mg AI | Benralizumab 30mg AFPS |
|---|---|---|
| Abdomen 55.0 to 69.9 kg | 18.83 ± 24.9 | 20.15 ± 21.8 |
| Abdomen 70.0 to 84.9 kg | 20.22 ± 21.0 | 17.43 ± 21.7 |
| Abdomen 85.0 to 100.0 kg | 19.59 ± 19.9 | 21.04 ± 21.7 |
| Thigh 55.0 to 69.9 kg | 18.58 ± 20.6 | 19.72 ± 21.4 |
| Thigh 70.0 to 84.9 kg | 19.93 ± 23.4 | 18.28 ± 17.9 |
| Thigh 85.0 to 100.0 kg | 19.02 ± 19.9 | 17.30 ± 11.5 |
| Upper arm 55.0 to 69.9 kg | 22.46 ± 13.6 | 17.30 ± 26.9 |
| Upper arm 70.0 to 84.9 kg | 20.54 ± 14.0 | 20.16 ± 25.3 |
| Upper arm 85.0 to 100.0 kg | 19.01 ± 26.9 | 19.42 ± 26.3 |
To evaluate the CL/F of Benralizumab administered to various anatomical injection sites and in subjects with different body weight ranges.
| mL/day | Benralizumab 30mg AI | Benralizumab 30mg AFPS |
|---|---|---|
| Abdomen 55.0 to 69.9 kg | 388.8 ± 34.3 | 388.9 ± 43.8 |
| Abdomen 70.0 to 84.9 kg | 462.9 ± 29.5 | 508.9 ± 33.2 |
| Abdomen 85.0 to 100.0 kg | 504.6 ± 18.3 | 402.7 ± 30.4 |
| Thigh 55.0 to 69.9 kg | 350.1 ± 32.6 | 281.1 ± 16.8 |
| Thigh 70.0 to 84.9 kg | 393.7 ± 29.6 | 325.9 ± 18.2 |
| Thigh 85.0 to 100.0 kg | 378.2 ± 26.8 | 406.0 ± 22.9 |
| Upper arm 55.0 to 69.9 kg | 345.8 ± 24.7 | 455.2 ± 29.8 |
| Upper arm 70.0 to 84.9 kg | 429.4 ± 19.5 | 366.1 ± 27.0 |
| Upper arm 85.0 to 100.0 kg | 532.6 ± 21.7 | 471.6 ± 20.3 |
To evaluate the Vz/F of Benralizumab administered to various anatomical injection sites and in subjects with different body weight ranges.
| Liters | Benralizumab 30mg AI | Benralizumab 30mg AFPS |
|---|---|---|
| Abdomen 55.0 to 69.9 kg | 10.56 ± 28.0 | 11.30 ± 28.4 |
| Abdomen 70.0 to 84.9 kg | 13.50 ± 30.4 | 12.79 ± 25.5 |
| Abdomen 85.0 to 100.0 kg | 14.26 ± 25.0 | 12.22 ± 15.8 |
| Thigh 55.0 to 69.9 kg | 9.386 ± 18.2 | 7.999 ± 15.5 |
| Thigh 70.0 to 84.9 kg | 11.32 ± 23.5 | 8.596 ± 13.5 |
| Thigh 85.0 to 100.0 kg | 10.38 ± 20.2 | 10.13 ± 21.0 |
| Upper arm 55.0 to 69.9 kg | 11.21 ± 21.2 | 11.36 ± 17.7 |
| Upper arm 70.0 to 84.9 kg | 12.72 ± 23.6 | 10.65 ± 18.7 |
| Upper arm 85.0 to 100.0 kg | 14.61 ± 23.0 | 13.21 ± 32.9 |
To evaluate safety and tolerability of Benralizumab
| Participants | Benralizumab 30mg AI | Benralizumab 30mg AFPS |
|---|---|---|
| Any AE | 50 | 46 |
| Death | 0 | 0 |
| Any SAE | 0 | 0 |
| Any AE leading to discontinuation | 0 | 0 |
To evaluate the immunogenicity of Benralizumab
| Participants | Benralizumab 30mg AI | Benralizumab 30mg AFPS |
|---|---|---|
| ADA prevalence (positive at any visit) | 2 | 6 |
| ADA incidence | 0 | 3 |
Collected over At pre-dose and 2 h post-dose (Day 1), Days 2, 4, 5, 6, 8, 15, 29, 43 and 57. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Benralizumab 30mg Autoinjector (AI) | 0/90 (0%) | 0/90 (0%) | 50/90 (55.6%) |
| Benralizumab 30mg Accessorized Pre-filled Syringe (AFPS) | 0/90 (0%) | 0/90 (0%) | 46/90 (51.1%) |
| Event | Benralizumab 30mg Autoinjector (AI) | Benralizumab 30mg Accessorized Pre-filled Syringe (AFPS) |
|---|---|---|
| NasopharyngitisInfections and infestations | 18/90 | 13/90 |
| HeadacheNervous system disorders | 14/90 | 5/90 |
| Oropharyngeal painRespiratory, thoracic and mediastinal disorders | 7/90 | 11/90 |
| CoughRespiratory, thoracic and mediastinal disorders | 1/90 | 5/90 |
| FatigueGeneral disorders | 5/90 | 1/90 |
| ToothacheGastrointestinal disorders | 4/90 | 3/90 |
| VomitingGastrointestinal disorders | 3/90 | 0/90 |
| Back painMusculoskeletal and connective tissue disorders | 3/90 | 1/90 |
| RhinitisInfections and infestations | 2/90 | 0/90 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 0/90 | 2/90 |
| Age, Continuous(Years) | Benralizumab 30mg Autoinjector (AI) | Benralizumab 30mg Accessorized Pre-filled Syringe (AFPS) | Total |
|---|---|---|---|
| Mean | 40.8 ± 10.8 | 41.1 ± 11.1 | 40.9 ± 10.9 |
| Sex: Female, Male(Participants) | Benralizumab 30mg Autoinjector (AI) | Benralizumab 30mg Accessorized Pre-filled Syringe (AFPS) | Total |
|---|---|---|---|
| Female | 17 | 16 | 33 |
| Male | 73 | 74 | 147 |
| Ethnicity (NIH/OMB)(Participants) | Benralizumab 30mg Autoinjector (AI) | Benralizumab 30mg Accessorized Pre-filled Syringe (AFPS) | Total |
|---|---|---|---|
| Hispanic or Latino | 1 | 2 | 3 |
| Not Hispanic or Latino | 89 | 88 | 177 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Benralizumab 30mg Autoinjector (AI) | Benralizumab 30mg Accessorized Pre-filled Syringe (AFPS) | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 2 | 3 | 5 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 5 | 5 | 10 |
| White | 83 | 80 | 163 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 2 | 2 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Jan 2017 to primary completion in Jul 2017, 6 months.
Results were first posted in Jul 2019, 1 year 11 months after primary completion.
Of 173 industry-sponsored phase 1 interventional studies under Asthma, half reached primary completion within 6 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 12. This study's 6 months is close to that.
Counting every sponsor, half of 200 studies reached it within 6 months; a quarter within 3 and three quarters within 14.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Benralizumab